Just two weeks after the multi-million dollar deal with US cancer specialist OncoC4, BioNTech has established another partnership – this time a multi-billion dollar partnership.
The company announced Monday that BioNTech has acquired two potential cancer drugs to treat solid tumors from Chinese biotech company DualityBio. DualityBio will receive a $170 million upfront payment under the partnership and be eligible for potentially more than $1.5 billion in contingent payments and tiered royalties on potential future product sales.
Agent specifically destroys cancer cells
Both agents belong to the class of so-called antibody-drug conjugates (ADCs), which are intended to target cancer cell destruction while preventing damage to healthy tissue. This therapy would be better tolerated than chemotherapy.
Pharmaceutical companies such as the British AstraZeneca and the Japanese Daiichi Sankyo therefore rely on this technology for their breast cancer drug Enhertu. The American drug manufacturer Pfizer recently announced the acquisition of the biotech company Seagen – one of the pioneers in the field of antibody-drug conjugates – for $43 billion announced.
Better than chemotherapy
Just two weeks ago, BioNTech secured a novel antibody to treat several OncoC4 solid tumors, for which the American cancer specialist will receive a $200 million upfront payment, as well as other success-related milestone payments and royalties.
Source: Krone
I am an experienced and passionate journalist with a strong track record in news website reporting. I specialize in technology coverage, breaking stories on the latest developments and trends from around the world. Working for Today Times Live has given me the opportunity to write thought-provoking pieces that have caught the attention of many readers.
